Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (NASDAQ: LTRN) generates a steady flow of news as an AI-driven, clinical-stage oncology company advancing both a precision medicine pipeline and a proprietary artificial intelligence platform. News coverage on this page centers on developments in its RADR® AI and machine learning platform, clinical trial milestones for LP-184, LP-284, and LP-300, regulatory interactions, and strategic initiatives that shape the company’s position in AI-enabled cancer drug development.
Investors and researchers following LTRN news will find detailed updates on Phase 1 and Phase 2 clinical trials, including safety and efficacy readouts, biomarker findings, and disease control observations in heavily pre-treated cancer patients. Recent announcements have highlighted LP-184’s Phase 1a results in advanced solid tumors, LP-284’s activity in relapsed or refractory B-cell lymphomas, and LP-300 data from the HARMONIC™ trial in never-smoker non-small cell lung cancer. Lantern also reports on FDA designations such as Fast Track, Orphan Drug, and Rare Pediatric Disease status that influence development pathways for its drug candidates.
In addition to clinical results, Lantern’s news stream covers the evolution of its RADR® platform and related AI modules. Articles describe the launch and performance of tools like predictBBB.ai for blood–brain barrier prediction and LBx-AI for liquid biopsy-based treatment response modeling, as well as presentations at scientific meetings and symposia. Corporate news items include quarterly financial updates, at-the-market financing agreements, board appointments, proxy statements, and the announcement of an AI Center of Excellence in Bengaluru, India to scale RADR® and multi-agent AI systems for global biopharma partners.
By reviewing the LTRN news feed, readers can track how Lantern integrates AI, genomics, and clinical data into its oncology programs, how regulators and collaborators engage with its pipeline, and how the company positions its AI modules and partnerships in the broader biopharmaceutical landscape. This page is a resource for monitoring material events, clinical inflection points, and platform advances that Lantern discloses through press releases and regulatory communications.
Lantern Pharma (LTRN) has announced the initiation of an Antibody Drug Conjugate (ADC) program, collaborating with Califia Pharma for development and evaluation. This program aims to target solid tumors and blood cancers using innovative linker technologies and DNA damage compounds, LP-100 and LP-184. Industry analysts project the global ADC market could exceed $10 billion by 2026. Lantern will leverage its RADR® A.I. platform to identify optimal cancer types and biomarker signatures for targeted therapies, intending to launch clinical trials by 2022.
Lantern Pharma (LTRN) announced a collaboration with Johns Hopkins to advance its LP-184 drug candidate for glioblastoma multiforme (GBM). This partnership aims to develop targeted applications for LP-184, utilizing patient-derived cancer models to enhance the understanding of its mechanisms. CEO Panna Sharma emphasized the significance of this collaboration in harnessing advanced methodologies and expanding the RADR® A.I. platform's data capabilities. The initiative seeks to improve patient outcomes in GBM, which has a grim five-year survival rate of only 5.5%.
Lantern Pharma (LTRN) announced promising preclinical data showing that its drug candidate, LP-184, can effectively cross the blood-brain barrier, crucial for treating Glioblastoma Multiforme (GBM). GBM, the most aggressive brain cancer, has a median survival of only 15 months and no current cure. The global GBM market is expected to reach $3.3 billion by 2024. Unlike standard treatments, LP-184 has a different mechanism of action, making it a potential option for patients resistant to current therapies. Lantern aims to accelerate clinical trials for LP-184, targeting a broader spectrum of CNS cancers.
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced its CEO, Panna Sharma, will participate in three virtual investor events this December. Notable events include the Diamond Equity Research Emerging Growth Invitational on December 1, 2020, and the Benzinga Global Small Cap Conference on December 9, 2020. Lantern Pharma utilizes its proprietary RADR® A.I. platform for oncology drug development, focusing on drug repurposing and improving patient outcomes by identifying suitable candidates based on genomic profiles.
Lantern Pharma Inc. (NASDAQ: LTRN) reported financial results for Q3 2020, highlighting significant advancements in oncology drug development and its proprietary AI platform, RADR®. The company has three compounds in development: LP-100 in Phase 2 for metastatic prostate cancer, LP-300 preparing for Phase 2 for non-small cell lung cancer, and LP-184 in preclinical stages for various cancers. Notably, RADR® surpassed one billion data points, enhancing the drug development process. Cash and equivalents stood at $20.8 million, marking a substantial rise from $1.2 million at 2019's end, while net losses increased to $1.7 million.
Lantern Pharma (LTRN) will host a conference call on October 29, 2020, at 4:00 p.m. ET to discuss its financial and operating results for the third quarter ending September 30, 2020. The call, led by CEO Panna Sharma, will be accessible via teleconference and online, with a replay available until November 29, 2020. Lantern Pharma focuses on drug discovery and development in oncology, utilizing its RADR® artificial intelligence platform to optimize therapeutic outcomes for patients.
Lantern Pharma (NASDAQ: LTRN) announced an enhanced collaboration with Georgetown University focusing on LP-184, a small molecule drug candidate for targeted treatment of certain solid tumors like prostate and pancreatic cancers. The initial phase yielded strong evidence of LP-184's efficacy, particularly in prostate cancer cells expressing PTGR1. Next steps involve expanding research to validate LP-184's mechanism of action and confirming genomic data which could lead to more personalized treatments. Lantern aims to streamline drug development costs using its RADR® AI platform.
Lantern Pharma (LTRN) has announced a collaboration with Fox Chase Cancer Center to advance the development of LP-184 for pancreatic cancer. The partnership aims to create a robust gene signature to enhance the efficacy of targeted therapies. CEO Panna Sharma emphasized the importance of collaborations in leveraging their RADR® A.I. platform for drug development. This agreement could streamline the path to clinical trials, potentially reducing costs and improving patient outcomes in a field where survival rates remain low. LP-184 is a next-generation alkylating agent currently in preclinical development.
Lantern Pharma (LTRN), a clinical-stage biopharmaceutical company, announced upcoming investor presentations for September 2020. CEO Panna Sharma will participate in several conferences, including the LD Micro 500 on September 1 at 2:40 p.m. ET, and the H.C. Wainwright Global Investor Conference on September 15 at 4:30 p.m. ET. The company utilizes its proprietary RADR® A.I. platform for oncology drug development, focusing on precision therapeutics. Interested investors can reach out for meetings through the provided contact information.
Lantern Pharma (LTRN), a clinical-stage biotechnology company, announced an upcoming interview with CEO Panna Sharma on The RedChip Money Report, airing on Bloomberg International on August 16, 2020, at 6 p.m. local time. The interview will cover the company’s A.I.-based drug discovery platform and ongoing clinical trials. Viewers can also access the segment on the Action Channel in the U.S. at 11 a.m. ET on the same day. Lantern Pharma focuses on using machine learning and genomics to develop targeted oncology drugs.